slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 32,191-32,220
Pages 1,371
Rows per page 30
Component
32,191-32,220 of 41,127
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
31
The slide uses a complex table structure to compare patient demographics and clinical outcomes across three cohorts.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
33
The slide uses a side-by-side comparison of two disease indications, each with its own clinical data points and relevant market benchmarks.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
39
The table compares CRS and ICANS incidence and management across three dosage groups (150x10^6, 450x10^6, and 800x10^6 cells).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
47
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
02
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
26
The slide uses a standard pharmaceutical pipeline table format with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
33
The slide uses a comparative structure to present data for two distinct indications side-by-side.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
42
Includes both internal unpublished data and external reference data from Winograd et al. (2015).Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
61
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
02
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Setup1 hit
05
The slide uses a split layout with a dark sidebar for branding and a large photo of the vehicle on the right.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Key Takeaways1 hit
18
Innoviz | Results Presentation Deck | 20 slidesInnoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Loop · Why Now1 hit
02
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · Attention1 hit
03
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · Attention1 hit
10
The slide uses stacked bar charts to show revenue composition across four segments: Data/Patient Network, Women's health, Rare diseases/Other, and Oncology.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
The slide uses a mix of bar charts and a line-bar combo chart to track operational and financial performance metrics over four quarters.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
18
Invitae | Results Presentation Deck | 27 slidesInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit
02
Kering | Fixed Income Presentation Deck | 35 slidesKering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit
06
The slide uses a grid layout to present six distinct KPIs, including financial results and sustainability milestones.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Problem1 hit
31
The chart shows the movement from 2,306m to 3,854m in net debt, including leverage ratios (0.3x to 0.5x).Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit
02
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
24
The slide highlights investment activities and financial health indicators.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
60
The chart shows the transition from 2,306m (0.3x) to 3,854m (0.5x) net debt.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
02
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
14
Includes error bars representing standard error of the mean; data points are plotted over 42 days.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit